Latest Advances

  • Condition: Early-Stage Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
  • Journal: Zhonghua wai ke za zhi [Chinese journal of surgery]
  • Treatment Used: Docetaxel, Carboplatin plus Trastuzumab Regimen
  • Number of Patients: 522
  • Published —
The aim of the study was to examine the effectiveness of docetaxel, carboplatin plus trastuzumab regimen (TCH) in early-stage human epidermal growth factor receptor 2 (HER2) positive breast cancer.
  • Condition: Breast Cancer Brain Metastases
  • Journal: BMC cancer
  • Treatment Used: Trastuzumab Emtansin with Stereotactic Radiation
  • Number of Patients: 16
  • Published —
In this study, researchers evaluated the safety and effectiveness of trastuzumab emtansin with stereotactic radiation for the treatment of HER2+ breast cancer brain metastases.
  • Condition: Triple-Negative Breast Cancer (TNBC)
  • Journal: The Journal of international medical research
  • Treatment Used: Polymerase Inhibitors (PARPis)
  • Number of Patients: NULL
  • Published —
This study evaluated the effectiveness and safety of polymerase inhibitors (targeted therapies that are used to treat cancer; PARPis) in patients with triple-negative breast cancer (cancer cells that don’t have estrogen or progesterone receptors and also don’t make too much of the protein called HER2; TNBC).
  • Condition: HER2-Positive Early Breast Cancer
  • Journal: The Lancet. Oncology
  • Treatment Used: Pertuzumab and Trastuzumab Subcutaneous Injection plus Chemotherapy
  • Number of Patients: 500
  • Published —
The study compared the outcomes between pertuzumab and trastuzumab subcutaneous injection plus chemotherapy for treating HER2-positive early breast cancer.
  • Condition: HER2-Positive Relapsed Breast Cancer Previously Treated with Taxanes, Anthracyclines, and Trastuzumab
  • Journal: Annals of palliative medicine
  • Treatment Used: Pyrotinib Combined with Carboplatin
  • Number of Patients: 1
  • Published —
This case report describes a patient with HER2-positive relapsed breast cancer who had acquired resistance to trastuzumab treated with three cycles of treatments of pyrotinib (400 mg, orally once per day, days 1-21) combined with carboplatin (600 mg, iv drip, day 1, cycled every 21 days).
  • Condition: HER2 Positive Breast Cancer
  • Journal: Technology in cancer research & treatment
  • Treatment Used: Tyrosine Kinase Inhibitors in the Combination Therapy
  • Number of Patients: 0
  • Published —
The study researched the safety and effectiveness of tyrosine kinase inhibitors in the combination therapy for HER2 positive breast cancer.
  • Condition: Breast Cancer
  • Journal: Technology in cancer research & treatment
  • Treatment Used: Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade
  • Number of Patients: 2758
  • Published —
This study investigated the pathological complete response (therapy is given prior to surgery for cancer, then once the patient undergoes surgery, the tissue removed that previously had been proven to contain cancer no longer contains any cancer cells when it is examined by the pathologist; pCR) rates of dual human epidermal growth factor receptor 2 (HER2) blockade in patients with breast cancer.
  • Condition: Metastatic HER2(+) Breast Cancer
  • Journal: BMC cancer
  • Treatment Used: Biosimilar BCD-022
  • Number of Patients: 225
  • Published —
This study assessed the safety and effectiveness of BCD-022 and reference trastuzumab in combination with paclitaxel in the treatment of metastatic HER2(+) breast cancer.
  • Condition: Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer
  • Journal: Scientific reports
  • Treatment Used: Neoadjuvant Chemotherapy
  • Number of Patients: 1097
  • Published —
This study investigated the correlation between neutrophil-to-lymphocyte ratio (NLR) and pathologic complete response (pCR) and survival outcomes in patients with human epidermal growth factor receptor 2 (HER2)-negative breast cancer who were treated with neoadjuvant chemotherapy.
  • Condition: Cervical Lymphadenopathy and Dermal Involvement in Patient with Recurrent Breast Cancer
  • Journal: Journal of investigative medicine high impact case reports
  • Treatment Used: Xeloda Oral, Trastuzumab, and Pertuzumab Combined Drug Therapy
  • Number of Patients: 1
  • Published —
This case report describes a 42-year-old woman diagnosed with recurrent breast cancer with supraclavicular lymphadenopathy and dermal involvement treated with 6 cycles (1 per month) of trastuzumab subcutaneous 600 mg, pertuzumab intravenous 840 mg (as an attack dose, later on 420 mg), and xeloda oral 1000 mg.
  • Condition: Early HER2-Positive Breast Cancer in South Africa
  • Journal: South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde
  • Treatment Used: Adjuvant Trastuzumab
  • Number of Patients: 0
  • Published —
This article explored data on the use of trastuzumab for the treatment of early HER2-positive breast cancer in South Africa.
  • Condition: Metastatic Breast Cancer
  • Journal: Scientific reports
  • Treatment Used: Physical Activity
  • Number of Patients: 833
  • Published —
The study researched the outcomes of physical activity in patients with metastatic breast cancer.
Showing 1-12 of 109